DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation
Interim Analysis Results Expected in Q1 2027
DiaMedica Therapeutics Inc.
Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction now Scheduled for November 24, 2026
Event to Include Results from First Two Phase 2 Early-Onset FGR Trial Cohorts
DiaMedica Therapeutics Inc.
Leading Maternal-Fetal Medicine Experts to Discuss FGR Disease State, the Clinical Rationale for DM199 (Rinvecalinase Alfa)
Early Safety and Trial Findings from First Cohort of Phase 2 Early-Onset FGR Trial to Be
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that
Enrollment Complete in First Cohort of Phase 2 Early-Onset Fetal Growth Restriction Trial; Key Opinion Leader Call and Topline Results to Be Held in September
Positive Topline Results from Phase 2 Late-Onset
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on
First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
DM199 is intended to improve maternal uterine artery blood
DiaMedica planning to conduct a rat pharmacokinetic and activity study, which it believes will address FDA-requested data for a preeclampsia IND
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the
ReMEDy2 Phase 2/3 AIS Trial of DM199 Surpasses 75% of Enrollment Required to Trigger Pre-Specified Interim Analysis
Interim Analysis by Independent DSMB Expected to Determine if a Sample Size Re-Estimation (Ranging
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that its
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced
